clinical trial · NCT07499232
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC·phase3·recruiting·n = 530
Crohn DiseaseGuselkumabRisankizumab
brief summary
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
started
Apr 21, 2026
primary completion
Nov 15, 2028
completion
Dec 11, 2030
last updated
Jul 6, 2026
official title
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol